<DOC>
	<DOCNO>NCT00697203</DOCNO>
	<brief_summary>This 4 arm study evaluate efficacy safety RO4607381 co-administered pravastatin patient low relatively low HDL-C level . Patients randomise one 4 group receive either RO4607381 300mg , 600mg 900mg po daily , placebo po daily , 12 weeks.All patient also receive pravastatin 40mg po daily 12 weeks.The anticipated time study treatment 3 month target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Assess Effect RO4607381 Patients With Relatively Low Levels High Density Lipoprotein-Cholesterol ( HDL-C )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>adult patient 1875 year age ; dyslipidemic patient low relatively low HDLC level treatment pravastatin . woman pregnant , breastfeeding , childbearing potential ; morbid obesity ; uncontrolled hypertension ; poorly control insulintreated diabetes ; high creatinine level history statinassociated myopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>